Business Description
Elicio Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US28657F1030
Total Employee Number:
33Description
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.04 | |||||
Equity-to-Asset | -0.06 | |||||
Debt-to-Equity | -9.98 | |||||
Debt-to-EBITDA | -0.38 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -2.7 | |||||
3-Year EPS without NRI Growth Rate | 2 | |||||
3-Year FCF Growth Rate | -3.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.31 | |||||
9-Day RSI | 25.99 | |||||
14-Day RSI | 29.63 | |||||
3-1 Month Momentum % | 30.73 | |||||
6-1 Month Momentum % | 75.94 | |||||
12-1 Month Momentum % | 78.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.24 | |||||
Quick Ratio | 2.24 | |||||
Cash Ratio | 2.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -26.8 | |||||
Shareholder Yield % | -41.21 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -1361.93 | |||||
ROA % | -149.38 | |||||
ROIC % | -398.62 | |||||
3-Year ROIIC % | 247.74 | |||||
ROC (Joel Greenblatt) % | -725.54 | |||||
ROCE % | -212.56 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -1.36 | |||||
EV-to-EBITDA | -1.4 | |||||
EV-to-FCF | -1.37 | |||||
Earnings Yield (Greenblatt) % | -73.53 | |||||
FCF Yield % | -72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Elicio Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.063 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 93.85 | ||
| 14-Day RSI | 29.63 | ||
| 14-Day ATR (€) | 0.506357 | ||
| 20-Day SMA (€) | 4.99 | ||
| 12-1 Month Momentum % | 78.63 | ||
| 52-Week Range (€) | 2.72 - 12.4 | ||
| Shares Outstanding (Mil) | 19.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Elicio Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Elicio Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 30 days | ||
| General meeting for 2026 | 2026-07-14 | In 6 days | ||
| Bank of America Healthcare Conference | 2026-05-14 12:20 | 8.75 (+0.57%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 8.30 (+0.61%) | ||
| Annual report for 2025 | 2026-03-12 | 10.10 (-6.48%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 10.10 (-6.48%) | ||
| the TD Cowen 46th Annual Health Care Conference | 2026-03-04 13:10 | 11.40 (-0.87%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 7.85 (+1.95%) | ||
| Second quarter earnings results for 2025 | 2025-08-07 | 7.70 (+0.65%) |
Show
Entries
Elicio Therapeutics Inc Frequently Asked Questions
What is Elicio Therapeutics Inc(FRA:9HA)'s stock price today?
The current price of FRA:9HA is €2.80. The 52 week high of FRA:9HA is €12.40 and 52 week low is €2.72.
When is next earnings date of Elicio Therapeutics Inc(FRA:9HA)?
The next earnings date of Elicio Therapeutics Inc(FRA:9HA) is 2026-08-07 Est..
Does Elicio Therapeutics Inc(FRA:9HA) pay dividends? If so, how much?
Elicio Therapeutics Inc(FRA:9HA) does not pay dividend.
Press Release
Articles on Elicio Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers